Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 8/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782086 | 0.97 | HTR2B (0.53) | HTR2BSLC6A7F10KLK1ABL1 | |
| SCHEMBL6782078 | 0.97 | HTR2B (0.53) | HTR2BSLC6A7F10KLK1ABL1 | |
| SCHEMBL6738660 | 0.88 | F10 (0.49) | HTR2BF10KLK1HRH4HRH3 | |
| SCHEMBL6730046 | 0.86 | F10 (0.49) | F10KLK1ABL1BCRHRH4 | |
| SCHEMBL6730038 | 0.86 | F10 (0.49) | HTR2BF10KLK1ABL1BCR | |
| SCHEMBL6726545 | 0.86 | METAP2 (0.46) | HTR2BF10GRM5METAP2METAP1 | |
| SCHEMBL6726550 | 0.86 | LMNA (0.45) | HTR2BF10KLK1GRM5 | |
| SCHEMBL6730406 | 0.85 | ALDH1A1 (0.43) | HTR2BF10KLK1 | |
| SCHEMBL6730408 | 0.85 | METAP2 (0.45) | HTR2BF10METAP2METAP1CBFB | |
| SCHEMBL6729184 | 0.85 | F10 (0.49) | F10KLK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | HTR2B 1053/4885SLC6A7 4827/4885F10 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.